ES2251200T3
(en)
|
1998-07-08 |
2006-04-16 |
Sanofi-Aventis Deutschland Gmbh |
SULPHONYLAMINOCARBOXYLIC ACID N-ARILAMIDS REPLACED WITH SULFUR, ITS USE AND PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM.
|
DE19943634A1
(en)
|
1999-09-13 |
2001-04-12 |
Bayer Ag |
Novel dicarboxylic acid derivatives with pharmaceutical properties
|
DE19943636A1
(en)
|
1999-09-13 |
2001-03-15 |
Bayer Ag |
Novel dicarboxylic acid derivatives with pharmaceutical properties
|
DE19943635A1
(en)
|
1999-09-13 |
2001-03-15 |
Bayer Ag |
Novel aminodicarboxylic acid derivatives with pharmaceutical properties
|
DE10109858A1
(en)
|
2001-03-01 |
2002-09-05 |
Bayer Ag |
Novel halogen-substituted aminodicarboxylic acid derivatives
|
DE10109859A1
(en)
|
2001-03-01 |
2002-09-05 |
Bayer Ag |
Novel aminodicarboxylic acid derivatives
|
DE10110749A1
(en)
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituted aminodicarboxylic acid derivatives
|
DE10110750A1
(en)
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Novel aminodicarboxylic acid derivatives with pharmaceutical properties
|
DE10220570A1
(en)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamate-substituted pyrazolopyridines
|
IL150509A
(en)
*
|
2002-07-01 |
2007-07-04 |
Joseph Kaspi |
Pharmaceutical compositions containing donepezil hydrocholoride
|
DE102005050498A1
(en)
|
2005-10-21 |
2007-06-06 |
Bayer Healthcare Aktiengesellschaft |
Cyclopropylacetic acid derivatives and their use
|
DE102005050377A1
(en)
|
2005-10-21 |
2007-04-26 |
Bayer Healthcare Ag |
Heterocyclic compounds and their use
|
DE102005050375A1
(en)
|
2005-10-21 |
2007-04-26 |
Bayer Healthcare Ag |
Tetrazole derivatives and their use
|
DE102005050497A1
(en)
|
2005-10-21 |
2007-04-26 |
Bayer Healthcare Ag |
Difluorophenol derivatives and their use
|
DE102005050376A1
(en)
|
2005-10-21 |
2007-05-31 |
Bayer Healthcare Ag |
Dicarboxylic acid derivatives and their use
|
DE102007015035A1
(en)
|
2007-03-29 |
2008-10-02 |
Bayer Healthcare Ag |
Substituted dibenzoic acid derivatives and their use
|
DE102007015034A1
(en)
|
2007-03-29 |
2008-10-02 |
Bayer Healthcare Ag |
Lactam-substituted dicarboxylic acids and their use
|
EP2197551B1
(en)
|
2007-09-06 |
2016-12-28 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
WO2009068652A1
(en)
|
2007-11-30 |
2009-06-04 |
Smithkline Beecham Corporation |
2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
|
TW200938529A
(en)
|
2007-12-03 |
2009-09-16 |
Smithkline Beecham Corp |
Compounds
|
WO2009123316A1
(en)
|
2008-04-04 |
2009-10-08 |
武田薬品工業株式会社 |
Heterocyclic derivative and use thereof
|
DE102008018675A1
(en)
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted carboxylic acid derivatives and their use
|
WO2010015652A2
(en)
|
2008-08-07 |
2010-02-11 |
Smithkline Beecham Corporation |
Thiazole compounds as activators of soluble guanylate cyclase
|
WO2010015653A1
(en)
|
2008-08-07 |
2010-02-11 |
Smithkline Beecham Corporation |
Pyrimidine derivatives as activators of soluble guanylate cyclase
|
JP5501369B2
(en)
|
2008-11-25 |
2014-05-21 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Soluble guanylate cyclase activator
|
TW201028152A
(en)
|
2009-01-20 |
2010-08-01 |
Merck & Co Inc |
Soluble guanylate cyclase activators
|
KR20110133034A
(en)
|
2009-02-26 |
2011-12-09 |
머크 샤프 앤드 돔 코포레이션 |
Soluble guanylate cyclase activators
|
DE102009012314A1
(en)
|
2009-03-09 |
2010-09-16 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted alkylcarboxylic acids and their use
|
CN101670106A
(en)
|
2009-09-22 |
2010-03-17 |
吉林大学 |
Natural activator of soluble guanylate cyclase
|
WO2011056511A2
(en)
|
2009-10-26 |
2011-05-12 |
Auspex Pharmaceuticals, Inc. |
4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
|
DE102009046115A1
(en)
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 3-phenylpropanoic acids and their use
|
WO2011115804A1
(en)
|
2010-03-17 |
2011-09-22 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
EP2549875B1
(en)
|
2010-03-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
DE102010020553A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 8-alkoxy-2-aminotetralin derivatives and their use
|
DE102010021637A1
(en)
*
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 5-fluoro-1H-pyrazolopyridines and their use
|
UA107112C2
(en)
|
2010-05-27 |
2014-11-25 |
Мерк Шарп Енд Доме Корп. |
Activator of soluble guanylate cyclase
|
DK2588465T3
(en)
|
2010-06-30 |
2017-05-01 |
Ironwood Pharmaceuticals Inc |
SGC stimulators
|
EP2632551B1
(en)
|
2010-10-28 |
2016-07-06 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
JP5878546B2
(en)
|
2010-11-09 |
2016-03-08 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
sGC stimulant
|
SG190296A1
(en)
|
2010-12-07 |
2013-06-28 |
Bayer Ip Gmbh |
Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
|
JP5715713B2
(en)
|
2011-03-10 |
2015-05-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Soluble guanylate cyclase activator
|
DE102011007272A1
(en)
*
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Branched 3-phenylpropionic acid derivatives and their use
|
BR112013030909A2
(en)
|
2011-05-30 |
2016-12-06 |
Astellas Pharma Inc |
imidazopyridine compounds
|
WO2013025425A1
(en)
|
2011-08-12 |
2013-02-21 |
Boehringer Ingelheim International Gmbh |
Soluble guanylate cyclase activators
|
WO2013101830A1
(en)
|
2011-12-27 |
2013-07-04 |
Ironwood Pharmaceuticals, Inc. |
2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
|
EP2840076B1
(en)
|
2012-04-16 |
2017-10-25 |
TOA Eiyo Ltd. |
Bicyclic compound
|
DE102012208530A1
(en)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituted piperidinoacetamides and their use
|
EP2874993B1
(en)
|
2012-07-20 |
2016-08-24 |
Bayer Pharma Aktiengesellschaft |
Substituted aminoindane- and aminotetralinecarboxylic acids and use thereof
|
ME02603B
(en)
|
2012-07-20 |
2017-06-20 |
Bayer Pharma AG |
Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
|
MX338887B
(en)
|
2012-09-07 |
2016-05-04 |
Boehringer Ingelheim Int |
Alkoxy pyrazoles as soluble guanylate cyclase activators.
|
WO2014047111A1
(en)
|
2012-09-18 |
2014-03-27 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
WO2014047325A1
(en)
|
2012-09-19 |
2014-03-27 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
US9624214B2
(en)
|
2012-11-05 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
|
EA027909B1
(en)
|
2012-11-30 |
2017-09-29 |
Астеллас Фарма Инк. |
Imidazopyridine compounds
|
ES2911276T3
(en)
|
2013-03-15 |
2022-05-18 |
Cyclerion Therapeutics Inc |
SGC stimulators
|
WO2015033307A1
(en)
|
2013-09-05 |
2015-03-12 |
Glaxosmithkline Intellectual Property Development Limited |
Novel soluble guanylate cyclase activators and their use
|
RU2673245C2
(en)
|
2013-10-15 |
2018-11-23 |
Тоа Эйо Лтд. |
4-aminomethylbenzoic acid derivatives
|
MX2016007522A
(en)
|
2013-12-11 |
2017-12-15 |
Ironwood Pharmaceuticals Inc |
Sgc stimulators.
|
WO2015088885A1
(en)
|
2013-12-11 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
US9783552B2
(en)
|
2013-12-11 |
2017-10-10 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
EP3152214B1
(en)
|
2014-06-04 |
2020-01-29 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
|
TW201625586A
(en)
|
2014-07-02 |
2016-07-16 |
諾華公司 |
Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
|
TW201625601A
(en)
|
2014-07-02 |
2016-07-16 |
諾華公司 |
Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
|
TW201625584A
(en)
|
2014-07-02 |
2016-07-16 |
諾華公司 |
Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
|
ES2784477T3
(en)
|
2014-07-22 |
2020-09-28 |
Boehringer Ingelheim Int |
Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
|
JP6624616B2
(en)
|
2014-09-17 |
2019-12-25 |
サイクレリオン・セラピューティクス,インコーポレーテッド |
sGC stimulant
|
US20170298055A1
(en)
|
2014-09-17 |
2017-10-19 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
WO2016044446A2
(en)
|
2014-09-17 |
2016-03-24 |
Ironwood Pharmaceuticals, Inc. |
Sgc stimulators
|
JP6678656B2
(en)
|
2014-09-19 |
2020-04-08 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Novel soluble guanylate cyclase activators and their use
|
TW201625635A
(en)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
ES2839248T5
(en)
*
|
2015-07-23 |
2024-02-22 |
Bayer Pharma AG |
Soluble guanylate cyclase (sGC) stimulators and/or activators in combination with a neutral endopeptidase inhibitor (NEP inhibitor) and/or an angiotensin AII antagonist and their use
|
CA3008776A1
(en)
|
2015-12-18 |
2017-06-22 |
Novartis Ag |
Indane derivatives and the use thereof as soluble guanylate cyclase activators
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017108441A1
(en)
|
2015-12-22 |
2017-06-29 |
Universiteit Maastricht |
Treatment of cognitive impairment with cgc stimulator
|
EP3872080B1
(en)
*
|
2016-09-02 |
2023-08-16 |
Cyclerion Therapeutics, Inc. |
Fused bicyclic sgc stimulators
|
EP3525779A1
(en)
*
|
2016-10-11 |
2019-08-21 |
Bayer Pharma Aktiengesellschaft |
Combination containing sgc stimulators and mineralocorticoid receptor antagonists
|